Pipeline Analysis

PUBLISHER: DelveInsight | PRODUCT CODE: 2023892

PUBLISHER: DelveInsight | PRODUCT CODE: 2023892

T-cell Malignancies - Epidemiology Forecast - 2036

PUBLISHED: April 1, 2026

PAGES: 216 Pages

DELIVERY TIME: 2-10 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

T-cell Malignancies Insights and Trends

According to DelveInsight's analysis, the total number of incident cases of T-cell malignanacies in the US were ~34,000 in the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan in 2025.
T-cell malignancies, encompassing Peripheral T-cell Lymphomas (PTCL) and cutaneous subtypes such as Cutaneous T-cell lymphoma (CTCL), represent a clinically heterogeneous and aggressive group of cancers with generally poorer outcomes than B-cell malignancies.
In CTCL, about 60% of patients are diagnosed at early Stages (IA/IB), which are typically indolent with near-normal life expectancy. However, ~30% may progress to advanced-stage disease, significantly worsening prognosis.
PTCL accounting for 10-15% of non-Hodgkin lymphomas in the US, 6.5% in EU and 25% in Japan. Incidence varies by region and subtype, with PTCL-NOS, AITL, and ALCL being the most common. Patients face poor prognosis, high relapse rates, and limited durable treatment options, contributing to significant clinical and quality-of-life burden.
The lack of reliable, disease-specific biomarkers in CTCL leads to delayed and uncertain diagnosis, reliance on repeated biopsies, and suboptimal treatment decisions, highlighting a critical need for biomarkers that enable early detection, accurate differentiation, and more durable, personalized therapy selection.

T-cell Malignancies Epidemiology Forecast

2025 Incident Cases of T-cell Malignancies: ~34,000
T-cell Malignancies Growth Rate (2026-2036): 1.2% CAGR

DelveInsight's 'T-cell Malignancies -Epidemiology Forecast - 2036' report delivers an in-depth understanding of the T-cell Malignancies, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

T-cell Malignancies Understanding and Diagnosis Algorithm

T-cell Malignancies Overview

T cell malignancies encompass a heterogeneous group of diseases, each reflecting a clonal evolution of dysfunctional T cells at various stages of development. T-cell lymphomas comprise approximately 10-15% of all Non-Hodgkin's Lymphomas (NHLs). The main subsets are peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

PTCLs refers to the nodal or systemic T-cell lymphomas and comprises 19 different entities with varying clinical and pathologic presentation including PTCL-not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and adult T-cell Leukemia/lymphoma (ATLL), a rare and aggressive T-cell lymphoma linked to human T-cell lymphotropic virus type 1 (HTLV-1). CTCL originates in the skin, including the main subtype's mycosisfungoides (MF) and Sezary syndrome. The various subtypes have distinct pathophysiology and molecular profiles. Beyond this, there is geographic diversity.

Diagnosis

Diagnosis of T-cell malignancies involves a stepwise approach integrating clinical evaluation, histopathology, and advanced laboratory testing. The initial step includes assessment of presenting symptoms such as skin lesions in CTCL or lymphadenopathy and systemic symptoms in PTCL. This is followed by tissue biopsy (skin, lymph node, or bone marrow), which remains the gold standard for diagnosis. Immunophenotyping using immunohistochemistry or flow cytometry is then performed to confirm T-cell lineage and characterize antigen expression. Molecular testing, including T-cell receptor (TCR) gene rearrangement and next-generation sequencing, is used to establish clonality and identify relevant mutations. Imaging techniques such as CT or PET-CT scans are further utilized to determine disease extent and staging, while bone marrow evaluation may be required in certain cases.

T-cell Malignancies Epidemiology

Key Findings from T-cell Malignancies Epidemiological Analysis and Forecast

According to DelveInsight's estimates, in 2025, the total number of incident cases of T-cell malignanacies in the US were ~15,500.
In the US, among type-specific T-cell malignancies, PTCL accounted for the majority of cases (~12,330) in 2025, whereas CTCL represented a smaller share with ~3,100 cases.
In Japan, the age-specific incident cases of CTCL in 2025 were higher in males (~890 cases), whereas females accounted for a comparatively lower number of cases (~560).
CTCL represents approximately 2-4% of all non-Hodgkin lymphomas, classifying it as an orphan malignancy. Mycosis fungoides is the predominant subtype, accounting for ~55-65% of CTCL cases. The disease is typically diagnosed in older adults, with a median age at onset of 55-65 years, and around 60-70% of patients present with early-stage disease at diagnosis.

Scope of the Report:

The report covers a segment of key events, an executive summary, a descriptive overview of T-cell malignancies, explaining their causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

T-cell Malignancies Patient Population Forecast

Report Key Strengths

Epidemiology-based (Epi-based) Bottom-up Forecasting
11-Year Forecast
Patient Burden Trends (By Geography)

FAQs:

What are the disease risks, burdens, and unmet needs of T-cell Malignancies? What will be the growth opportunities across the 7MM concerning the patient population with T-cell Malignancies?
What is the historical and forecasted T-cell Malignancies patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Product Code: DIEI1693

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology and Market Forecast Methodology

5. Market Overview at a Glance

5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM

6. Disease Background and Overview of T-cell Malignancies

6.1. Introduction
6.2. Classification
- 6.2.1. CTCL
- 6.2.2. PTCL
6.3. Symptoms
6.4. Stages
6.5. Pathogenesis
- 6.5.1. Molecular Pathogenesis of CTCL
- 6.5.2. Molecular Pathogenesis of PTCL
6.6. Diagnosis

7. Epidemiology and Patient Population of T-cell Malignancies

7.1. Key Findings
7.2. Total Incident Cases of T-cell Malignancies in the 7MM
- 7.2.1. Total Incident Cases of CTCL in the 7MM
- 7.2.2. Total Incident Cases of PTCL in the 7MM
7.3. CTCL Patient Burden
- 7.3.1. Assumptions and Rationale
- 7.3.2. The United States
  - 7.3.2.1. Total Incident Cases of CTCL in the United States
  - 7.3.2.2. Type-specific Cases of CTCL in the United States
  - 7.3.2.3. Gender-specific Cases of CTCL in the United States
  - 7.3.2.4. Stage-specific Cases of CTCL in the United States
  - 7.3.2.5. Treatment-Eligible Pool For Early and Advanced Stages in the United States
- 7.3.3. EU4 and the UK
  - 7.3.3.1. Total Incident Cases of CTCL in EU4 and the UK
  - 7.3.3.2. Type-specific Cases of CTCL in EU4 and the UK
  - 7.3.3.3. Gender-specific Cases of CTCL in EU4 and the UK
  - 7.3.3.4. Stage-specific Cases of CTCL in EU4 and the UK
  - 7.3.3.5. Treatment-Eligible Pool For Early and Advanced Stages in EU4 and the UK
- 7.3.4. Japan
  - 7.3.4.1. Total Incident Cases of CTCL in Japan
  - 7.3.4.2. Type-specific Cases of CTCL in Japan
  - 7.3.4.3. Gender-specific Cases of CTCL in Japan
  - 7.3.4.4. Stage-specific Cases of CTCL in Japan
  - 7.3.4.5. Treatment-Eligible Pool For Early and Advanced Stages in Japan
7.4. PTCL Patient Burden
- 7.4.1. Assumptions and Rationale
- 7.4.2. The United States
  - 7.4.2.1. Total Incident Cases of PTCL in the United States
  - 7.4.2.2. Stage-specific Incident Cases of PTCL in the United States
  - 7.4.2.3. Subtype-specific Incident Cases of PTCL in the United States
  - 7.4.2.4. Line-Wise Treated Cases of PTCL in the United States
- 7.4.3. EU4 and the UK
  - 7.4.3.1. Total Incident Cases of PTCL in EU4 and the UK
  - 7.4.3.2. Stage-specific Incident Cases of PTCL in EU4 and the UK
  - 7.4.3.3. Subtype-specific Incident Cases of PTCL in EU4 and the UK
  - 7.4.3.4. Line-Wise Treated Cases of PTCL in EU4 and the UK
- 7.4.4. Japan
  - 7.4.4.1. Total Incident Cases of PTCL in Japan
  - 7.4.4.2. Stage-specific Incident Cases of PTCL in Japan
  - 7.4.4.3. Subtype-specific Incident Cases of PTCL in Japan
  - 7.4.4.4. Line-Wise Treated Cases of PTCL in Japan

8. Appendix

8.1. Bibliography
8.2. Report Methodology

9. Delveinsight Capabilities

10. Disclaimer

11. About Delveinsight

Product Code: DIEI1693

List of Tables

Table 1: Summary of T-Cell Malignancies Market and Epidemiology (2022 ? 2036)
Table 2: Lymphomatoid Papulosis: Histologic Subtypes and Differential Diagnosis
Table 3: Old and New Who Classifications of PTCLs
Table 4: Subtypes of PTCL
Table 5: TMNB Classification For Mycosis Fungoides and Sezary Syndrome
Table 6: Suggested Regimens: Skin-Directed Therapies
Table 7: Stage IA Mycosis Fungoides (Limited Skin Involvement Alone; <10% BSA)
Table 8: Stage IB Mycosis Fungoides (Skin Only Disease With ?10% Bsa) - Stage IIA Mycosis Fungoides
Table 9: Stage IIB Mycosis Fungoides (Tumor Stage Disease)
Table 10: Stage III Mycosis Fungoides (Erythrodermic Disease)
Table 11: Sezary Syndrome (Stage IVA1 Or IVA2)
Table 12: Stage IV Mycosis Fungoides (Non-Sezary/Visceral Organ Disease) and Mycosis Fungoides With Large Cell Transformation (Mycosis Fungoides-Lct)
Table 13: Total Incident Cases of T-Cell Malignancies in the 7MM (2022 ? 2036)
Table 14: Total Incident Cases of CTCL in the 7MM (2022 ? 2036)
Table 15: Total Incident Cases of PTCL in the 7MM (2022 ? 2036)
Table 16: Total Incident Cases of CTCL in the US (2022 ? 2036)
Table 17: Type-specific Cases of CTCL in the US (2022 ? 2036)
Table 18: Gender-specific CTCL Cases in the US (2022 ? 2036)
Table 19: Stage-specific Cases of CTCL in the US (2022 ? 2036)
Table 20: Treatment-Eligible Pool For Early and Advanced Stages in the US (2022 ? 2036)
Table 21: Total Incident Cases of CTCL in EU4 and the UK (2022 ? 2036)
Table 22: Type-specific Cases of CTCL in EU4 and the UK (2022 ? 2036)
Table 23: Gender-specific Cases of CTCL in EU4 and the UK (2022 ? 2036)
Table 24: Stage-specific Cases of CTCL in EU4 and the UK (2022 ? 2036)
Table 25: Treatment-Eligible Pool For Early and Advanced Stages in EU4 and the UK (2022 ? 2036)
Table 26: Total Incident Cases of CTCL in Japan (2022 ? 2036)
Table 27: Type-Specific Cases of CTCL in Japan (2022 ? 2036)
Table 28: Gender-Specific CTCL Cases in Japan (2022 ? 2036)
Table 29: Stage-Specific Cases of CTCL in Japan (2022 ? 2036)
Table 30: Treatment-Eligible Pool For Early and Advanced Stages in Japan (2022 ? 2036)
Table 31: Total Incident Cases of PTCL in the US (2022 ? 2036)
Table 32: Stage-Specific Incident Cases of PTCL in the US (2022 ? 2036)
Table 33: Subtype-Specific Incident Cases of PTCL in the US (2022 ? 2036)
Table 34: Line-wise Treated Cases of PTCL in the United States (2022 ? 2036)
Table 35: Total Incident Cases of PTCL in EU4 and the UK (2022 ? 2036)
Table 36 Stage-specific Incident Cases of PTCL in Germany (2022 ? 2036)
Table 37: Stage-specific Incident Cases of PTCL in France (2022 ? 2036)
Table 38: Stage-specific Incident Cases of PTCL in Italy (2022 ? 2036)
Table 39: Stage-specific Incident Cases of PTCL in Spain (2022 ? 2036)
Table 40: Stage-specific Incident Cases of PTCL in the UK (2022 ? 2036)
Table 41: Stage-specific Incident Cases of PTCL in EU4 and the UK (2022 ? 2036)
Table 42: Subtype-specific Incident Cases of PTCL In Germany (2022 ? 2036)
Table 43: Subtype-specific Incident Cases of PTCL In France (2022 ? 2036)
Table 44: Subtype-specific Incident Cases of PTCL In Italy (2022 ? 2036)
Table 45: Subtype-specific Incident Cases of PTCL In Spain (2022 ? 2036)
Table 46: Subtype-specific Incident Cases of PTCL In The Uk (2022 ? 2036)
Table 47: Subtype-specific Incident Cases of PTCL in EU4 and the UK (2022 ? 2036)
Table 48: Line-wise Treated Cases of PTCL in Germany (2022 ? 2036)
Table 49: Line-wise Treated Cases of PTCL in France (2022 ? 2036)
Table 50: Line-wise Treated Cases of PTCL in Italy (2022 ? 2036)
Table 51: Line-wise Treated Cases of PTCL in Spain (2022 ? 2036)
Table 52: Line-wise Treated Cases of PTCL in the UK (2022 ? 2036)
Table 53: Line-wise Treated Cases of PTCL in EU4 and the UK (2022 ? 2036)
Table 54: Total Incident Cases of PTCL in Japan (2022 ? 2036)
Table 55: Stage-specific Incident Cases of PTCL in Japan (2022 ? 2036)
Table 56: Subtype-specific Incident Cases of PTCL in Japan (2022 ? 2036)
Table 57: Line-Wise Treated Cases of PTCL in Japan (2022 ? 2036)

List of Figures

Figure 1: Role of Cytokines in the Development of a TH2-biased Inflammatory Milieu Through the Modulation of Chemokines
Figure 2: Spectrum of Recurrently Mutated Signaling Pathways in CTCL
Figure 3: Total Incident cases of T-cell Malignancies in the 7MM (2022-2036)
Figure 4: Total Incident Cases of CTCL in the 7MM (2022-2036)
Figure 5: Total Incident cases of PTCL in the 7MM (2022-2036)
Figure 6: Total Incident Cases of CTCL in the US (2022-2036)
Figure 7: Type-specific Cases of CTCL in the US (2022-2036)
Figure 8: Gender-specific CTCL Cases in the US (2022-2036)
Figure 9: Stage-specific Cases of CTCL in the US (2022-2036)
Figure 10: Treatment-eligible Pool for Early and Advanced Stages in the US (2022-2036)
Figure 11: Total Incident Cases of CTCL in EU4 and the UK (2022-2036)
Figure 12: Type-specific Cases of CTCL in EU4 and the UK (2022-2036)
Figure 13: Gender-specific Cases of CTCL in EU4 and the UK (2022-2036)
Figure 14: Stage-specific Cases of CTCL in EU4 and the UK (2022-2036)
Figure 15: Treatment-eligible Pool for Early and Advanced Stages in EU4 and the UK (2022-2036)
Figure 16: Total Incident Cases of CTCL in the Japan (2022-2036)
Figure 17: Type-specific Cases of CTCL in Japan (2022-2036)
Figure 18: Gender-specific CTCL Cases in Japan (2022-2036)
Figure 19: Stage-specific Cases of CTCL in Japan (2022-2036)
Figure 20: Treatment-eligible Pool for Early and Advanced Stages in Japan (2022-2036)
Figure 21: Total Incident Cases of PTCL in the United States (2022-2036)
Figure 22: Stage-specific Incident Cases of PTCL in the United States (2022-2036)
Figure 23: Subtype-specific Incident Cases of PTCL in the United States (2022-2036)
Figure 24: Line-wise Treated Cases of PTCL in the United States (2022-2036)
Figure 25: Total Incident Cases of PTCL in EU4 and the UK (2022-2036)
Figure 26: Stage-specific Incident Cases of PTCL in EU4 and the UK (2022-2036)
Figure 27: Subtype-specific Incident Cases of PTCL in EU4 and the UK (2022-2036)
Figure 28: Line-wise Treated Cases of PTCL in EU4 and the UK (2022-2036)
Figure 29: Total Incident Cases of PTCL in Japan (2022-2036)
Figure 30: Stage-specific Incident Cases of PTCL in Japan (2022-2036)
Figure 31: Subtype-specific Incident Cases of PTCL in Japan (2022-2036)
Figure 32: Line-wise Treated Cases of PTCL in Japan (2022-2036)

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

T-cell Malignancies - Epidemiology Forecast - 2036

Description

Table of Contents

List of Tables

T-cell Malignancies Epidemiology

Scope of the Report:

Report Insights

Report Key Strengths

FAQs:

Reasons to Buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology and Market Forecast Methodology

5. Market Overview at a Glance

6. Disease Background and Overview of T-cell Malignancies

7. Epidemiology and Patient Population of T-cell Malignancies

8. Appendix

9. Delveinsight Capabilities

10. Disclaimer

11. About Delveinsight

List of Tables

List of Figures